Evidence map›Paper›PMID 28427463›Full record

SynthesisDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2017

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis.

Fardin Dolatimehr, Hamidreza Karimi-Sari, Mohammad Saeid Rezaee-Zavareh, Seyed Moayed Alavian, Bita Behnava, Mohammad Gholami-Fesharaki, Heidar Sharafi

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?Medical archives (Sarajevo, Bosnia and Herzegovina) · 2018
    Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fardin DolatimehrStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Hamidreza Karimi-SariStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad Saeid Rezaee-ZavarehStudent Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Seyed Moayed AlavianMeta-analysis Study Group, Iran Hepatitis Network, Tehran, Iran.
Bita BehnavaMeta-analysis Study Group, Iran Hepatitis Network, Tehran, Iran.
Mohammad Gholami-FesharakiDepartment of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Heidar SharafiMeta-analysis Study Group, Iran Hepatitis Network, Tehran, Iran. h.sharafi@meldcenter.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) infection is an important cause of chronic liver disease which has been affected 3% of world's population. Some studies have shown that adding Sofosbuvir (SOF), an HCV polymerase inhibitor to the conventional therapy of Pegylated-interferon (PegIFN) plus Ribavirin (RBV) can increase the rate of sustained virologic response (SVR) among HCV-infected patients. This study was conducted to determine the effect of combination therapy with PegIFN and RBV plus SOF for chronic hepatitis C genotype 1 infection using systematic review with meta-analysis.

methodsIn this study, electronic databases including PubMed, Scopus, Science Direct, and Web of Science were comprehensively searched using appropriate strategies containing all related keywords of "hepatitis C", "PegIFN", "RBV" and "SOF". Studies assessed the efficacy of combination therapy with PegIFN and RBV plus SOF for chronic hepatitis C genotype 1 infection were included in the meta-analysis.

resultsAfter screening of 757 records, we included five articles with total sample size of 411 to the meta-analysis. Based on the fixed-effect model (χ

conclusionsCombination therapy with PegIFN and RBV plus SOF results in high treatment response in patients with HCV genotype 1 infection.

Indexed as

Antiviral AgentsDrug Therapy, CombinationHepacivirusHepatitis C, ChronicHumansInterferon-alphaRibavirinSofosbuvirAntiviral AgentsInterferon-alphaRibavirinSofosbuvirHepatitis CMeta-analysisPegylated-interferonRibavirinSofosbuvir

Identifiers

PMID28427463
PMCPMC5397824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.